A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

Exclusion Criteria

• •Previous radioimmunotherapy. Previous antibody-based therapy is allowed as long as ≥ 28 days has elapsed from last dose to study treatment.
• •Prior radiation to \> 30% of the red marrow or to maximal tolerable level for any organ
• •Serious cardiac condition within the last 6 months
• •Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, with the exception of antimicrobials that are considered to be essential for care of the patient
• •History of retinal degenerative disease, history of uveitis, history of retinal vein occlusion (RVO), or any eye condition that would be considered a risk factor for RVO or has medically relevant abnormalities identified on screening ophthalmologic examination
• •Active central nervous system (CNS) malignant disease in subjects with a history of CNS malignancy. Subjects with stable, prior, or currently treated brain metastases are allowed.
• •Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)
• •Known autoimmune disease
• •Active infection requiring intravenous (IV) antibiotic usage within the last week prior to the dosimetry portion of the study
• •Corticosteroid use within 2 weeks of study treatment
• •Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or confound the interpretation of study results
• •Pregnant or breast-feeding